OrthoPediatrics (NASDAQ:KIDS) Hits New 1-Year High Following Analyst Upgrade

Key Points

• OrthoPediatrics shares hit a new 52-week high after Truist raised its price target to $28.00; the stock traded as high as $29.75. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $30.75.
• Third-quarter revenue rose 19% year over year to $72.7 million, exceeding estimates, and management raised 2026 revenue guidance to $270 million–$273 million. The FDA also cleared the company’s PNP Femur Retrograde Nail System, expanding its pediatric orthopedic product portfolio.
• Profitability remains a concern: OrthoPediatrics reported a quarterly loss of $0.23 per share, while major shareholders sold shares and insiders have sold 2.1 million shares worth approximately $46.7 million over the past three months.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report)'s share price hit a new 52-week high during trading on Wednesday after Truist Financial raised their price target on the stock from $22.00 to $28.00. Truist Financial currently has a hold rating on the stock. OrthoPediatrics traded as high as $29.75 and last traded at $30.1440, with a volume of 570,726 shares trading hands. The stock had previously closed at $23.82.

Several other research analysts have also issued reports on the company. Canaccord Genuity Group set a $30.00 target price on OrthoPediatrics in a research report on Wednesday. BTIG Research lifted their price target on OrthoPediatrics from $29.00 to $30.00 and gave the company a "buy" rating in a research report on Wednesday. Piper Sandler restated an "overweight" rating and set a $30.00 price target (up from $25.00) on shares of OrthoPediatrics in a research report on Wednesday. TD Cowen upped their price target on OrthoPediatrics from $23.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Lake Street Capital reiterated a "buy" rating and issued a $38.00 price objective on shares of OrthoPediatrics in a report on Wednesday. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $30.75.

Insider Activity at OrthoPediatrics

In related news, major shareholder Jennifer Pritzker sold 326,700 shares of the business's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the sale, the insider owned 6,536,764 shares of the company's stock, valued at $150,607,042.56. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Squadron Capital Llc sold 326,700 shares of the company's stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the completion of the sale, the insider owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. This trade represents a 4.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,100,000 shares of company stock valued at $46,747,931 in the last three months. Company insiders own 32.50% of the company's stock.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Record revenue and raised guidance: Third-quarter revenue reached $72.7 million, up 19% year over year and ahead of analysts’ approximately $68.5 million estimate. Management raised 2026 revenue guidance to $270 million-$273 million, signaling continued demand for the company’s pediatric orthopedic products. OrthoPediatrics third-quarter results and guidance
• Positive Sentiment: New product approval expands growth opportunities: The FDA granted 510(k) clearance for the PNP Femur Retrograde Nail System, expanding OrthoPediatrics’ Pediatric Nailing Platform for femoral trauma and deformity correction. The company also completed its first implantations, providing an early commercial milestone. FDA clearance and first implantations
• Positive Sentiment: Investor confidence improved after the earnings call: Management highlighted the record quarterly performance and raised outlook, reinforcing the company’s growth narrative and helping explain the increased trading activity. Q3 2026 earnings call highlights
• Neutral Sentiment: Losses remain a consideration: OrthoPediatrics reported a quarterly loss of $0.23 per share. This was better than one published consensus estimate of a $0.25 loss, but below another estimate of a $0.21 loss, making the earnings result mixed rather than a clear bottom-line beat. OrthoPediatrics Q3 earnings analysis

Institutional Trading of OrthoPediatrics

Several hedge funds and other institutional investors have recently made changes to their positions in KIDS. GAMMA Investing LLC increased its position in OrthoPediatrics by 70.3% during the 3rd quarter. GAMMA Investing LLC now owns 1,165 shares of the company's stock valued at $26,000 after buying an additional 481 shares in the last quarter. Waverly Advisors LLC boosted its holdings in OrthoPediatrics by 6.7% in the second quarter. Waverly Advisors LLC now owns 12,366 shares of the company's stock worth $237,000 after acquiring an additional 775 shares in the last quarter. Legal & General Group Plc bought a new position in shares of OrthoPediatrics during the second quarter valued at $34,000. Quantinno Capital Management LP bought a new position in shares of OrthoPediatrics during the first quarter valued at $160,000. Finally, R Squared Ltd bought a new position in shares of OrthoPediatrics during the first quarter valued at $212,000. Hedge funds and other institutional investors own 69.05% of the company's stock.

OrthoPediatrics Trading Up 28.0%

The firm has a 50-day moving average price of $23.02 and a 200-day moving average price of $19.41. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. The stock has a market cap of $796.28 million, a PE ratio of -18.10 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.02). OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. The firm had revenue of $72.66 million during the quarter, compared to the consensus estimate of $68.50 million. As a group, equities analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.